C12N 2710/16422
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16422 (New viral proteins or individual genes, new structural or functional aspects of) appears on 56 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 56
- Published applications
- 42
- Assignees
- 39
- Inventors
- 100
- Latest grant
- 20 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 10 | 0 |
| 1999 | 6 | 0 |
| 2000 | 6 | 0 |
| 2001 | 6 | 0 |
| 2002 | 3 | 3 |
| 2003 | 6 | 1 |
| 2004 | 1 | 4 |
| 2005 | 2 | 3 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 3 | 5 |
| 2012 | 2 | 4 |
| 2013 | 2 | 3 |
| 2014 | 0 | 2 |
| 2015 | 2 | 0 |
| 2016 | 2 | 1 |
| 2017 | 0 | 0 |
| 2018 | 2 | 1 |
| 2019 | 0 | 1 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 1 |
| 2024 | 0 | 2 |
| 2025 | 0 | 5 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Transcription active complex targeting cancer drug from viral protein sequence20 Jan 2026US 12,528,840 B2The Regents of the University of California
- Inhibition of TCR signaling with peptide variants21 Jan 2020US 10,538,558 B2Signablok, Inc.
- Inhibition of TCR signaling with peptide variants27 Nov 2018US 10,138,276 B2Signablok, Inc.
- Method of enhancing KSHV LANA1 immunogenicity17 Jul 2018US 10,022,438 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- DNA virus MicroRNA and methods for inhibiting same25 Oct 2016US 9,476,048 B2The Rockefeller University
- Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors16 Jul 2026US 2026/0199414 A1Turnstone Biologics Corp.
- Engineered gene effectors, compositions, and methods of use thereof25 Dec 2025US 2025/0388634 A1Epicrispr Biotechnologies, Inc.
- Peptide inhibitors for chromodomain helicase dna binding protein 4 (chd4)11 Sep 2025US 2025/0282834 A1The Regents of the University of California
- vIRF3-Derived Peptide and Use Thereof for Preventing or Treating Cancer21 Aug 2025US 2025/0263444 A1Korea University Research and Business Foundation, Sejong Campus
- Use of viral il-6 in cancer therapy26 Jun 2025US 2025/0206796 A1The Regents of the University of California
Most cited
By later US patents
- Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof80US 5,854,398 AThe Trustees of Columbia University in the City of New York · 1998
- Terminal complement inhibitor fusion proteins31US 5,847,082 AAlexion Pharmaceuticals, Inc. · 1998
- Unique associated Kaposi's sarcoma virus sequences and uses thereof18US 6,348,586 B1The Trustees of Columbia University in the City of New York · 2002
- Unique associated Kaposi's sarcoma virus sequences and uses thereof15US 5,801,042 AThe Trustees of Columbia University in the City of New York · 1998
- Unique associated Kaposi's sarcoma virus sequences and uses thereof15US 5,830,759 AThe Trustees of Columbia University in the City of New York · 1998